AstraZeneca has entered into a deal worth up to $6.9bn with Daiichi Sankyo to develop and commercialise cancer drug trastuzumab...
Read More...
The post AstraZeneca and Daiichi Sankyo sign $6.9bn cancer drug development deal appeared first on Pharmaceutical Technology.
Original Article: AstraZeneca and Daiichi Sankyo sign $6.9bn cancer drug development deal